Navigation Links
Avastin Unsuccessful as Adjuvant Therapy in Setting of Stage II and III Colon Cancer but May Be Effective if Given for Longer Duration
Date:5/30/2009

Cancer researchers from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Allegheny General Hospital (AGH) in Pittsburgh reported today at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando that use of the drug bevacizumab (Avastin) in combination with standard chemotherapy was not effective in prolonging disease-free survival (DFS) among patients with stage II and stage III colon cancer when given for one year. There is promise that using Avastin for periods longer than one year will lead to improved efficacy.

Pittsburgh, PA/Orlando, FL (Vocus) May 30, 2009 -- Cancer researchers from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Allegheny General Hospital (AGH) in Pittsburgh will report today at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando that use of the drug bevacizumab (Avastin) in combination with standard chemotherapy was not effective in prolonging disease-free survival (DFS) in patients with stage II and stage III colon cancer when given for one year. There is promise that using Avastin for periods longer than one year will lead to improved efficacy.

Approved by the U.S. Food and Drug Administration in 2004 for the treatment of metastatic colorectal cancer and subsequently for the treatment of breast and lung cancer, Avastin is a medicine that interferes with the growth of cancer cells by inhibiting the formation of new blood vessels in cancerous tumors.

According to Norman Wolmark, M.D., principal investigator and chairman of both the NSABP and AGH’s Department of Human Oncology, the study being presented at ASCO is the first to explore use of Avastin in the adjuvant setting for patients with earlier stages of colon cancer.

Between September, 2004 and October, 2005, 2,710 patients with stage II and stage III colon cancer were randomized in the prosp
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Surveyed Experts Indicate That the Combination of Sutent and Taxol Has Advantages Over the Combination of Avastin and Taxol in the Treatment of Metastatic Triple-Negative Breast Cancer
2. Avastin effective at delaying brain tumor progression in recurrent disease
3. Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017
4. Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
5. Avastin and Other Emerging Agents Will Drive the Glioma Drug Market to More Than $1.8 Billion in 2017
6. Genentech/Roche/Chugais Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
7. Avastin Added to Chemo Helps Women With Advanced Breast Cancer
8. Avastin Added to Chemo Helps Women With Advanced Cancer
9. Off-Label Avastin Use for Wet Macular Degeneration
10. FDA OKs Avastin for Advanced Breast Cancer
11. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , ... July 07, 2015 , ... America is blessed ... California Casualty’s Nominate A Hero program offers a special way to say “thanks.” ... hero receives a $250 gift card and their place on the “Wall of Heroes.” ...
(Date:7/7/2015)... AURORA, Colo. (PRWEB) , ... ... ... healthcare landscape relies on highly educated and motivated leaders with strong managerial ... how well they clearly communicate with patients, staff, providers, business partners, insurance ...
(Date:7/7/2015)... Toronto, ON (PRWEB) , ... July 07, 2015 , ... ... which is effective immediately and permits the use of gluten-free claims for gluten free ... the prospect of expanding the Gluten-Free Certification Program (GFCP) to include gluten-free ...
(Date:7/7/2015)... ... July 07, 2015 , ... CSG ... have been selected by the Department of Vermont Health Access to provide Quality ... Information System (MMIS) and Integrated Contact Center System project. , Vermont is implementing ...
(Date:7/6/2015)... , ... July 06, 2015 , ... ... pre-clinical stages of drug discovery. iPSCs are generated from adult cells, such as ... any cell type in the human body. , iPSC-derived cardiomyocytes ...
Breaking Medicine News(10 mins):Health News:California Casualty Wants to Know: "Who Is Your Hero?" 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 3Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 4Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 4Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 4
... the damage to their lungs that exacerbates asthmatic symptoms just ... the University of Groningen in the Netherlands. The ... American Thoracic Society,s American Journal of Respiratory and Critical ... smoke appears to increase the thickness of the epithelium, or ...
... become a mainstay of multiple myeloma treatment may outperform ... who have received stem cell transplants from unrelated, partially ... be presented by Dana-Farber Cancer Institute investigators ... on Sunday, Dec. 6 (Abstract 48, Ernest N. Morial ...
... College of Wisconsin, in Milwaukee, found a substantial variation ... disease complications in children. Barriers to its use on ... identified. The study led by Amanda M. Brandow, ... College and Children,s Research Institute at the Children,s Hospital ...
... Hamilton, ON. Dec. 6, 2009 A new study provides ... as venous thromboembolism (VTE). The condition is estimated ... occurs when an abnormal clot forms in a vein and ... some cases, the clot may detach from its point of ...
... NEW ORLEANSA new three-drug combination has shown in a phase ... regimen" in the treatment of patients newly diagnosed with multiple ... say researchers from Dana-Farber Cancer Institute. Partial responses or ... with the drug combination in the multi-center study, with 74 ...
... , --In Youngest ... , PHILADELPHIA and NEW ORLEANS, Dec. 5 Pediatric ... with another gene to drive an often-fatal form of leukemia ... expect to better predict which infants may benefit from particular ...
Cached Medicine News:Health News:Quitting smoking can reverse asthma-inducing changes in lungs 2Health News:Bortezomib shows promise in reducing GVHD and reconstituting immune system in some patients 2Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4
(Date:7/6/2015)...  OrthoSpace Ltd. ("OrthoSpace" or "Company") announced today ... its US Investigational Device Exemption (IDE) pivotal study.  ... blinded control study that compares the Company,s InSpace ... repair for the treatment of full thickness massive ... available outside of the United States ...
(Date:7/6/2015)... , July 6, 2015 /CNW/ - The Canadian Pharmacists Association ... immunization strategy to ensure that all Canadians have the ... HPV (human papillomavirus) through immunization. The lack of access ... Canada is needlessly putting the health ... such as HPV, continue to pose a significant threat ...
(Date:7/6/2015)... 6, 2015 Mauna Kea ... multidisciplinary confocal laser endomicroscopy platform, announced today it ... Ministry of Health, Labor and Welfare (MHLW) ... the AQ-Flex 19 miniprobe.   Used ... miniprobe is comprised of a fiber-optic microscope that ...
Breaking Medicine Technology:OrthoSpace Enrolls First Patients in US IDE Study 2CPhA Calls for HPV Strategy for Young Men to Save Lives 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: